Abemaciclib (Verzenio) - A Third CDK 4/6 Inhibitor for Breast Cancer
Abemaciclib (Verzenio) - A Third CDK 4/6 Inhibitor for Breast Cancer
November 6, 2017 (Issue: 1533)
The FDA has approved abemaciclib (Verzenio – Lilly),
an oral cyclin-dependent kinase (CDK) 4/6 inhibitor,
for treatment of hormone receptor (HR)-positive,
human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast...more
- MN Dickler et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res 2017; 23:5218.
- GW Sledge, Jr. et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017; 35:2875.
- MP Goetz et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017 Oct 2 (epub).
- A Di Leo et al. MONARCH 3: abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer. Presented at the European Society for Medical Oncology (ESMO) Annual Meeting, Madrid, Spain, September 8-12, 2017. Abstract 2360_PR.
- Inhibitors and inducers of CYP enzymes and p-glycoprotein. Med Lett Drugs Ther 2017 September 18 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf. Accessed Oct ober 26, 2017.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Abemaciclib (Verzenio) - A Third CDK 4/6 Inhibitor for Breast Cancer
Article code: 1533e
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
